Zogenix's long-acting hydrocodone meets chronic pain endpoint, ready for 2012 filing
This article was originally published in Scrip
Executive Summary
Zogenix said that its Zohydro product, an extended-release capsule formulation of hydrocodone bitartrate without acetaminophen (paracetamol), met the primary endpoint vs placebo in a pivotal Phase III trial to treat chronic pain, paving the way for regulatory review by the US FDA in early 2012.